Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by porksnifferon Mar 15, 2019 9:02pm
102 Views
Post# 29494564

RE:No gain in BookValue in 4 years

RE:No gain in BookValue in 4 years
bigzig wrote: Book was $980 m in 2016, $991 m in 2018 and $1030 m in 2018.

But, Knight has yet to pay $42 million owed CRA.
Remove that and Book is $988 m.

Essentially no change at all.

Over this time period, the share price has declined to the current level which is barely above Book.

In addition, Knight remains Ebitda negative.

This is failure to execute of the worst sort..




This is incorrect.

Knight has deposited the $23,340 to the CRA last July and to RQ $18,242 in February 2019. So the $787 million in cash icludes this provision but the $18,242 is not as it was just paid in Q1 and will be reflected in next financials. So cash balance including the entire amount is presently $769 million. Keep in mind these are marked as 'other receivables' because they have started the appeals process and if they win will get the money right back leaving $811 million on the balance sheet.
Bullboard Posts